Novartis' innovative drug Nolasiban has been approved for the treatment of IgA nephropathy in China.

On August 20th, Novartis announced that their innovative product Nourida has been approved by the National Medical Products Administration for the treatment of proteinuria in adult patients with primary IgA nephropathy at risk of rapid disease progression. Nourida is the first non-immune therapy approved in China for treating IgA nephropathy, and is currently the only highly selective endothelin A receptor antagonist for this indication domestically.